var data={"title":"Quinupristin and dalfopristin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Quinupristin and dalfopristin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6888?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=quinupristin-and-dalfopristin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Quinupristin and dalfopristin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Quinupristin and dalfopristin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216636\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Synercid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216637\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Synercid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216659\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Streptogramin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216639\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Skin and skin structure infection, complicated:</b> IV: 7.5 mg/kg every 12 hours for at least 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bacteremia (methicillin-resistant <i>Staphylococcus aureus</i>) (off-label use):</b> IV: 7.5 mg/kg every 8 hours (Liu 2011). <b>Note:</b> May be considered with vancomycin failure and when reduced susceptibility to vancomycin and daptomycin is present.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Infective endocarditis (methicillin-resistant <i>Staphylococcus aureus</i>), treatment (off-label use):</b> IV: 7.5 mg/kg every 8 hours with or without additional antibiotics (Chesi 2006; ESC [Habib 2015]). Additional data is necessary to further define the role of quinupristin/dalfopristin in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Infective endocarditis (multidrug-resistant <i>Enterococcus faecium</i>), treatment (off-label use):</b> IV: 7.5 mg/kg every 8 hours with other antibiotics (eg, high-dose ampicillin or the combination of doxycycline and rifampin) (ESC [Habib 2015]; Matsumura 1998; Thompson 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Intravascular catheter-associated bloodstream infection (methicillin-resistant coagulase negative staphylococci or ampicillin- and vancomycin-resistant <i>E. faecium</i>) (off-label use):</b> IV: 7.5 mg/kg every 8 hours (IDSA [Mermel 2009])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216652\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Quinupristin and dalfopristin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Skin and skin structure infection, complicated: </b>Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216640\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216641\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216642\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, pharmacokinetic data suggest dosage adjustment may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216618\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synercid&reg;: 500 mg: Quinupristin 150 mg and dalfopristin 350 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216604\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216620\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Line should be flushed with 5% dextrose in water prior to and following administration. Infusion should be completed over 60 minutes (toxicity may be increased with shorter infusion). If severe venous irritation occurs following peripheral administration, quinupristin/dalfopristin may be further diluted (to 500 mL or 750 mL), infusion site changed, or infused by a central venous catheter. In general, administration by central venous catheter is required to avoid phlebitis (Kullar 2016; O'Driscoll 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216619\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Skin and skin structure infections, complicated:</b> Treatment of complicated skin and skin structure infections caused by methicillin-susceptible <i>Staphylococcus aureus</i> or <i>Streptococcus pyogenes</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25731760\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bacteremia (methicillin-resistant Staphylococcus aureus); Infective endocarditis (methicillin resistant Staphylococcus aureus), treatment (adults); Infective endocarditis (multidrug resistant Enterococcus faecium), treatment (adults); Intravascular catheter-associated bloodstream infection (methicillin-resistant coagulase negative staphylococci or ampicillin- and vancomycin-resistant E. faecium)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216611\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (3% to 35%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local pain (40% to 44%), local inflammation (at infusion site: 38% to 42%), localized edema (17% to 18%), infusion site reaction (12% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&le;47%), myalgia (&le;47%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Thrombophlebitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (2% to 3%), headache (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3%), pruritus (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase (3%), increased gamma-glutamyl transferase (2%), hyperglycemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3% to 5%), vomiting (3% to 4%), diarrhea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anaphylactoid reaction, anxiety, apnea, blood coagulation disorder, brain disease, cardiac arrhythmia, chest pain, confusion, constipation, dermal ulcer, diaphoresis, dizziness, dysautonomia, dyspepsia, dyspnea, fever, gastrointestinal hemorrhage, gout, hematuria, hemolysis, hemolytic anemia, hepatitis, hyperkalemia, hypersensitivity reaction, hypertonia, hypoglycemia, hyponatremia, hypotension, hypoventilation, hypovolemia, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, infection, insomnia, leg cramps, maculopapular rash, mesenteric artery occlusion, myasthenia, neck stiffness, neuropathy, oral candidiasis, ostealgia, palpitations, pancreatitis, pancytopenia, paraplegia, paresthesia, pericarditis, peripheral edema, phlebitis, pleural effusion, pseudomembranous colitis, respiratory distress, seizure, shock, stomatitis, syncope, thrombocytopenia, tremor, urticaria, vaginitis, vasodilatation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216623\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to quinupristin, dalfopristin, other streptogramins (eg, pristinamycin, virginiamycin), or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216608\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arthralgias/myalgias: May cause arthralgias and/or myalgias, sometimes severe; reversible with treatment discontinuation. Reduction of dosing frequency has led to improvement in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperbilirubinemia: May cause hyperbilirubinemia (&gt;5 times ULN; primarily conjugated bilirubin) possibly through competition for excretory pathways.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Phlebitis: May cause pain and phlebitis when infused through a peripheral line (not relieved by hydrocortisone or diphenhydramine).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216654\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216613\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9515&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Quinupristin may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216625\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6055734\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if quinupristin/dalfopristin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering quinupristin/dalfopristin to a nursing woman. The increased molecular weight of quinupristin/dalfopristin may minimize excretion into human milk. Nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13493234\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Culture and sensitivity, conjugated bilirubin if clinically indicated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216607\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Quinupristin/dalfopristin inhibits bacterial protein synthesis by binding to different sites on the 50S bacterial ribosomal subunit thereby inhibiting protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216622\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Quinupristin: 0.45 L/kg; Dalfopristin: 0.24 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Quinupristin is conjugated with glutathione and cysteine to active metabolites; dalfopristin is hydrolyzed to an active metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Quinupristin: 0.85 hour; Dalfopristin: 0.7 hour (mean elimination half-lives, including metabolites: 3 and 1 hours, respectively) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (75% to 77% as unchanged drug and metabolites); urine (15% to 19%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323773\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Synercid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150-350 mg (1): $486.82</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038795\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Pyostacine (BE, LU);</li>\n      <li>Synercid (FR, GR, HN, IT, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26373316\"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015]. <i>Circulation</i>. 2015;132(15):1435-1486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bryson HM and Spencer CM, &ldquo;Quinupristin/Dalfopristin,&rdquo; <i>Drugs</i>, 1996, 52(3):406-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/8875130/pubmed\" target=\"_blank\" id=\"8875130\">8875130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chant C and Rybak MH, &ldquo;Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(10):1022-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/8845540/pubmed\" target=\"_blank\" id=\"8845540\">8845540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chesi G, Colli A, Mestres CA, Gambarati G, Boni F, Gherli T. Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus. <i>BMC Infect Dis</i>. 2006;6:124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/16872491/pubmed\" target=\"_blank\" id=\"16872491\">16872491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11062197\"></a>Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. <i>J Antimicrob Chemother</i>. 2000;46(5):775-784.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/11062197/pubmed\" target=\"_blank\" id=\"11062197\">11062197</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10991879\"></a>Fuchs PC, Barry AL, Brown SD. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. <i>Antimicrob Agents Chemother</i>. 2000;44(10):2880-2882.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/10991879/pubmed\" target=\"_blank\" id=\"10991879\">10991879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griswold MW, Lomaestro BM, and Briceland LL, &ldquo;Quinupristin-Dalfopristin (RP 59500): An Injectable Streptogramin Combination,&rdquo; <i>Am J Health Syst Pharm</i>, 1996, 53:2045-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/8870891/pubmed\" target=\"_blank\" id=\"8870891\">8870891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). <i>Eur Heart J</i>. 2015;36(44):3075-3128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/26320109/pubmed\" target=\"_blank\" id=\"26320109\">26320109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26565015\"></a>Kullar R, Sakoulas G, Deresinski S, van Hal SJ. When sepsis persists: a review of MRSA bacteraemia salvage therapy. <i>J Antimicrob Chemother</i>. 2016;71(3):576-586.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/26565015/pubmed\" target=\"_blank\" id=\"26565015\">26565015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children: Executive Summary,&rdquo; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9868693\"></a>Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. <i>Clin Infect Dis</i>. 1998;27(6):1554-1556.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/9868693/pubmed\" target=\"_blank\" id=\"9868693\">9868693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10543762\"></a>Matsumura SO, Louie L, Louie M, Simor AE. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents. <i>Antimicrob Agents Chemother</i>. 1999;43(11)2776-2779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/10543762/pubmed\" target=\"_blank\" id=\"10543762\">10543762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published corrections appear in <i>Clin Infect Dis</i>. 2010;50(7):1079 and <i>Clin Infect Dis</i>. 2010;50(3):457]. <i>Clin Infect Dis</i>. 2009;49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. <i>Infect Drug Resist</i>. 2015;8:217-230.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/26244026/pubmed\" target=\"_blank\" id=\"26244026\">26244026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olsen KM, Rebuck JA, and Rupp ME, &ldquo;Arthralgias and Myalgias Related to Quinupristin-Dalfopristin Administration,&rdquo; <i>Clin Infect Dis</i>, 2001, 32(4):e83-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/11181142/pubmed\" target=\"_blank\" id=\"11181142\">11181142</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synercid (quinupristin dalfopristin) [prescribing information]. New York, NY: Pfizer Injectables; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14515928\"></a>Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. <i>South Med J</i>. 2003;96(8):818-820.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/14515928/pubmed\" target=\"_blank\" id=\"14515928\">14515928</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9515 Version 101.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F216636\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F216637\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F216659\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F216639\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F216652\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F216640\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F216641\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F216642\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F216618\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F216604\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F216620\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F216619\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25731760\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216611\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F216623\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F216608\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F216654\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F216613\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F216625\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6055734\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13493234\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F216607\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F216622\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323773\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038795\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9515|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=quinupristin-and-dalfopristin-patient-drug-information\" class=\"drug drug_patient\">Quinupristin and dalfopristin: Patient drug information</a></li><li><a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">Quinupristin and dalfopristin: Pediatric drug information</a></li></ul></div></div>","javascript":null}